I agree that this site is using cookies. You can find further informations here.
X
Bulian, P
71  results:
Search for persons X
?
1

Clinical utility of circulating tumor DNA qualification and..:

Pirosa, M. C. ; Bruscaggin, A. ; Terzi di Bergamo, L....
Hematological Oncology.  41 (2023)  S2 - p. 319-321 , 2023
Link: https://doi.org/10.1002/..
 
?
2

MOLECULAR CLUSTERING ON CTDNA IMPROVES THE PROGNOSTIC STRAT..:

Moia, R. ; Talotta, D. ; Dondolin, R....
Hematological Oncology.  41 (2023)  S2 - p. 174-175 , 2023
Link: https://doi.org/10.1002/..
 
?
3

S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BA..:

Pirosa, M. C. ; Bruscaggin, A. ; Terzi di Bergamo, L....
HemaSphere.  6 (2022)  - p. 126-127 , 2022
Link: https://doi.org/10.1097/..
 
?
4

IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RI..:

Condoluci, A. ; Terzi‐di‐Bergamo, L. ; Forestieri, G....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
5

CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC ..:

Spina, V. ; Pirosa, M. C. ; Bruscaggin, A....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
6

The German Hodgkin Study Group risk model is useful for Hod..:

Furlan, C. ; Matrone, F. ; Rupolo, M....
Cancer/Radiothérapie.  23 (2019)  5 - p. 378-384 , 2019
Link: https://doi.org/10.1016/..
 
?
7

EP-1246: Radiotherapy after autologous stem cell transplant..:

Matrone, F. ; Furlan, C. ; Rupolo, M....
Radiotherapy and Oncology.  127 (2018)  - p. S689 , 2018
Link: https://doi.org/10.1016/..
 
?
8

NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARA..:

Pozzo, F. ; Bittolo, T. ; Vendramini, E....
Hematological Oncology.  35 (2017)  S2 - p. 57-58 , 2017
Link: https://doi.org/10.1002/..
 
?
9

NOTCH1-mutated chronic lymphocytic leukemia cells are chara..:

Pozzo, F ; Bittolo, T ; Vendramini, E...
Leukemia.  31 (2017)  11 - p. 2407-2415 , 2017
Link: https://doi.org/10.1038/..
 
?
10

CD49d prevails over the novel recurrent mutations as indepe..:

Dal Bo, M ; Bulian, P ; Bomben, R...
Leukemia.  30 (2016)  10 - p. 2011-2018 , 2016
Link: https://doi.org/10.1038/..
 
?
11

PO-0665: Compliance with ILROG guidelines in the treatment ..:

Furlan, C. ; Bulian, P. ; Michieli, M....
Radiotherapy and Oncology.  119 (2016)  - p. S310 , 2016
Link: https://doi.org/10.1016/..
 
?
12

PO-0666: Comparing the efficacy of low-dose radiotherapy in..:

Furlan, C. ; Bulian, P. ; Michieli, M....
Radiotherapy and Oncology.  119 (2016)  - p. S311 , 2016
Link: https://doi.org/10.1016/..
 
?
13

Interim Analysis Results of a Phase 2 Trial of Low-Dose Rad..:

Furlan, C. ; Bulian, P. ; Spina, M....
International Journal of Radiation Oncology*Biology*Physics.  90 (2014)  1 - p. S80 , 2014
Link: https://doi.org/10.1016/..
 
?
14

Management of infectious mixed cryoglobulinemia: Clinical o..:

Mauro, E. ; Dal Maso, L. ; Ermacora, A....
Digestive and Liver Disease.  46 (2014)  - p. e18 , 2014
Link: https://doi.org/10.1016/..
 
?
15

CD3-CD16+ (NK) cells are rapidly and markedly affected by i..:

Ferrarini, A.M. ; Perini, P. ; Sivieri, S....
Journal of Neuroimmunology.  90 (1998)  1 - p. 97 , 1998
Link: https://doi.org/10.1016/..
 
1-15